Scotland's Ardana raises L2 million

5 April 2001

Ardana Bioscience of Scotland, which focuses on reproductive healthproducts, has received a L2 million ($2.8 million) funding boost from a founder shareholder, UK Medical Ventures Fund. This brings to L3.1 million the amount raised by Ardana since it was established in the middle of 2000.

Chief executive Simon Best said that the additional funding will enable Ardana "to accelerate our most promising research initiatives, some of which have the potential to enter clinical trials within the next two years." He added that the firm will look to establish collaborations "with relevant industry players" in the near future.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight